Drugs & Aging

, Volume 21, Issue 1, pp 19–41

Pharmacological Treatments for Persistent Non-Malignant Pain in Older Persons

Therapy In Practice

Abstract

Persistent non-malignant pain is common, often neglected and under-treated among older persons. Some older adults do not complain because they consider chronic pain to be a characteristic of normal aging. Physicians have concerns regarding adverse effects of pharmacological treatment.

The model of the World Health Organization for treatment of cancer pain is generally accepted and also recommended for persistent non-cancer pain. Furthermore, non-pharmacological treatment should complement drug treatment whenever possible. An initial assessment and possible treatment of underlying causes of pain are pertinent.

Modern pharmacological pain management is based on non-opioid and opioid analgesics. NSAIDs are among the most widely prescribed class of drugs in the world. The new cyclo-oxygenase-2 inhibitors such as celecoxib and rofecoxib offer an alternative for the treatment of mild-to-moderate pain in patients with a history of gastric ulcers or bleeding. Paracetamol (acetaminophen) is being used widely for the management of mild pain across all age groups as it has moderate adverse effects at therapeutic dosages.

For moderate pain, a combination of non-opioid analgesics and opioid analgesics with moderate pain relief properties (e.g. oxycodone, codeine, tramadol and tilidine/naloxone) is recommended. For severe pain, a combination of non-opioid analgesics and opioid analgesics with strong pain relief properties (e.g. morphine, codeine) is recommended.

The least toxic means of achieving systemic pain relief should be used. For continuous pain, sustained-release analgesic preparations are recommended. Drugs should be given on a fixed time schedule, and possible adverse effects and interactions should be carefully monitored. Adjuvant drugs, such as antidepressants or anticonvulsants, can be very effective especially in the treatment of certain types of pain, such as in diabetic neuropathy. Effective pain management should result in decreased pain, increased function and improvement in mood and sleep.

References

  1. 1.
    Helme RD, Gibson SJ. Pain in older people. In: Crombie IK, Croft PR, Linton SJ, et al., editors. Epidemiology of pain. Seattle: IASP Press, 1996: 103–12Google Scholar
  2. 2.
    Nikolaus T. Assessment of chronic pain in the elderly [in German]. Ther Umsch 1997; 54: 340–4PubMedGoogle Scholar
  3. 3.
    Gagliese L, Melzack R. Age differences in the quality of chronic pain: a preliminary study. Pain Res Manag 1997; 2: 157–62Google Scholar
  4. 4.
    Crook J, Rideout E, Browne G. The prevalence of pain complaints in a general population. Pain 1984; 18: 299–314PubMedCrossRefGoogle Scholar
  5. 5.
    Brattberg G, Parker MG, Thorslund M. A longitudinal study of pain: reported pain from middle age to old age. Clin J Pain 1997; 13: 144–9PubMedCrossRefGoogle Scholar
  6. 6.
    Badley EM, Tennat A. Changing profile of joint disorders with age: findings from a postal survey of the population of Calderdale, West Yorkshire, United Kingdom. Ann Rheum Dis 1992; 51: 366–71PubMedCrossRefGoogle Scholar
  7. 7.
    Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995; 38: 19–28PubMedCrossRefGoogle Scholar
  8. 8.
    Sternbach RA. Survey of pain in the United States: the Nuprin pain report. Clin J Pain 1986; 2: 49–53CrossRefGoogle Scholar
  9. 9.
    Andersson HI, Ejilertsson G, Leden I, et al. Chronic pain in a geographically defined population: studies of differences in age, gender, social class and pain localization. Clin J Pain 1993; 9: 174–82PubMedCrossRefGoogle Scholar
  10. 10.
    Cooner E, Amorosi S. The study of pain in older Americans. New York: Louis Harris and Associates, 1997Google Scholar
  11. 11.
    Roy R, Thomas M. A survey of chronic pain in an elderly population. Can Fam Physician 1986; 32: 513–6PubMedGoogle Scholar
  12. 12.
    Roy R, Thomas MR. Elderly persons with and without pain: a comparative study. Clin J Pain 1987; 3: 102–6CrossRefGoogle Scholar
  13. 13.
    Brattberg G, Parker MG, Thorslund M. The prevalence of pain among the oldest old in Sweden. Pain 1996; 67: 29–34PubMedCrossRefGoogle Scholar
  14. 14.
    Brochet B, Michel P, Barberger-Gateau P, et al. Population-based study of pain in elderly people: a descriptive survey. Age Ageing 1998; 27: 279–84CrossRefGoogle Scholar
  15. 15.
    Ferrell BA, Ferrell BR, Osterweil D. Pain in the nursing home. J Am Geriatr Soc 1990; 38: 409–14PubMedGoogle Scholar
  16. 16.
    Scudds RJ, Robertson JM. Empirical evidence of the association between the presence of musculoskeletal pain and physical disability in community-dwelling senior citizens. Pain 1998; 75: 229–35PubMedCrossRefGoogle Scholar
  17. 17.
    Casten RJ, Parmelee PA, Kleban MH, et al. The relationships among anxiety, depression, and pain in a geriatric institutionalized sample. Pain 1995; 61: 271–6PubMedCrossRefGoogle Scholar
  18. 18.
    Parmelee PA, Katz IR, Lawton MP. The relation of pain to depression among instituionalized aged. J Gerontol 1991; 46: P15–21PubMedCrossRefGoogle Scholar
  19. 19.
    Williamson GM, Schulz R. Pain, activity restriction, and symptoms of depression among community-residing adults. J Gerontol 1992; 47: 367–72CrossRefGoogle Scholar
  20. 20.
    Magni G, Caldieron C, Rigatti-Luchini S, et al. Chronic musculoskeletal pain and depressive symptoms in the general population: an analysis of the 1st National Health and Nutrition Examination Survey data. Pain 1990; 43: 299–307PubMedCrossRefGoogle Scholar
  21. 21.
    Lichtenstein MJ, Dhanda R, Cornell JE, et al. Disaggregating pain and its effect on physical functional limitations. J Gerontol 1998; 53: M361–71Google Scholar
  22. 22.
    Helme RD, Katz B, Gibson SJ, et al. Multidisciplinary pain clinics for older people: do they have a role? Clin Geriatr Med 1996; 12: 563–82PubMedGoogle Scholar
  23. 23.
    Blyth FM, March LM, Brnabic AJ, et al. Chronic pain in Australia: a prevalence study. Pain 2001; 89: 127–34PubMedCrossRefGoogle Scholar
  24. 24.
    Mantyselka P, Kumpusalo E, Ahonen R, et al. Pain as a reason to visit the doctor: a study in Finnish primary health care. Pain 2001; 89: 175–80PubMedCrossRefGoogle Scholar
  25. 25.
    Lavsky-Shulan M, Wallace RB, Kohout FJ, et al. Prevalence and functional correlates of low back pain in the elderly: the Iowa 65+ Rural Health Study. J Am Geriatr Soc 1985; 33: 23–8PubMedGoogle Scholar
  26. 26.
    Sengstaken EA, King SA. The problem of pain and its detection among geriatric nursing home residents. J Am Geriatr Soc 1994; 41: 541–4Google Scholar
  27. 27.
    Ferrell BA, Ferrell BR, Rivera I. Pain in cognitively impaired nursing home patients. J Pain Symptom Manage 1995; 10: 591–8PubMedCrossRefGoogle Scholar
  28. 28.
    Bernabei R, Gambassi G, Lapane K, et al. Management of pain in elderly patients with cancer. SAGE Study Group (Systematic Assessment of Geriatric Drug Use via Epidemiology). JAMA 1998; 279: 1877–82PubMedCrossRefGoogle Scholar
  29. 29.
    Weiner D, Peterson B, Ladd K, et al. Pain in nursing home residents: an exploration of prevalence, staff perspectives and practical aspects of measurement. Clin J Pain 1999; 15: 92–101PubMedCrossRefGoogle Scholar
  30. 30.
    Weiner D, Peterson B, Logue P, et al. Predictors of pain selfreport in nursing home residents. Aging Clin Exp Res 1998; 10: 411–20Google Scholar
  31. 31.
    Feldt KS, Ryden MB, Miles S. Treatment of pain in cognitively impaired compared with cognitively intact older patients with hip-fracture. J Am Geriatr Soc 1998; 46: 1079–85PubMedGoogle Scholar
  32. 32.
    Farrell MJ, Katz B, Helme RD. The impact of dementia on the pain experience. Pain 1996; 67: 612–9CrossRefGoogle Scholar
  33. 33.
    Duggleby W, Lander J. Cognitive status and postoperative pain: older adults. J Pain Symptom Manage 1994; 9: 19–27PubMedCrossRefGoogle Scholar
  34. 34.
    Marzinski LR. The tragedy of dementia: clinically assessing pain in the confused, nonverbal elderly. J Gerontol Nurs 1991; 17: 25–8PubMedGoogle Scholar
  35. 35.
    Avorn J, Gurwitz JH. Drug use in the nursing home. Ann Intern Med 1995; 123: 195–204PubMedGoogle Scholar
  36. 36.
    Cutler RB, Fishbain DA, Rosomoff RS, et al. Outcomes in treatment of pain in geriatric and younger age groups. Arch Phys Med Rehabil 1994; 75: 457–64PubMedCrossRefGoogle Scholar
  37. 37.
    Gibson SJ, Helme RD. Age-related differences in pain perception and report. Clin Geriatr Med 2001; 17: 433–56PubMedCrossRefGoogle Scholar
  38. 38.
    Chakour MC, Gibson SJ, Bradbeer M, et al. The effect of age on A-delta and C-fibre thermal pain perception. Pain 1996; 64: 143–52PubMedCrossRefGoogle Scholar
  39. 39.
    Sorkin BA, Rudy TE, Hanlon RB, et al. Chronic pain in old and young patients: differences appear less important than similarities. J Gerontol 1990; 45: P64–8PubMedCrossRefGoogle Scholar
  40. 40.
    Gibson SJ, Voukelatos X, Ames D, et al. An examination of pain perception and cerebral event-related potentials following carbon dioxide laser stimulation in patients with Alzheimer’s disease and age-matched control volunteers. Pain Res Manag 2001; 6: 126–32PubMedGoogle Scholar
  41. 41.
    AGS Panel on Persistent Pain in Older Persons. The management of persistent pain in older persons: American Geriatrics Society. J Am Geriatr Soc 2002; 50: S205–24CrossRefGoogle Scholar
  42. 42.
    Feldt KS, Warne MA, Ryden MB. Examining pain in aggressive cognitively impaired older adults. J Gerontol Nurs 1998; 24: 14–22PubMedGoogle Scholar
  43. 43.
    Grossberg GT, Sherman LK, Fine PG. Pain and behavioural disturbancies in the cognitively impaired older adult: assessment and treatment issues. Ann Long Term Care 2000; 8: 22–4Google Scholar
  44. 44.
    Miller J, Neelon V, Dalton J, et al. The assessment of discomfort in elderly confused patients: a preliminary study. J Neurosci Nurs 1996; 28: 175–82PubMedCrossRefGoogle Scholar
  45. 45.
    Weiner D, Hanlon J. Pain in nursing home residents: management strategies. Drugs Aging 2001; 18: 13–29PubMedCrossRefGoogle Scholar
  46. 46.
    Won A, Lapane K, Gambassi G, et al. Correlates and management of nonmalignant pain in the nursing home. J Am Geriatr Soc 1999; 47: 936–42PubMedGoogle Scholar
  47. 47.
    Ferrell BA. Pain evaluation and management in the nursing home. Ann Intern Med 1995; 123: 681–7PubMedGoogle Scholar
  48. 48.
    AGS Panel on Chronic Pain in Older Persons. The management of chronic pain in older persons: American Geriatrics Society. J Am Geriatr Soc 1998; 46: 635–51Google Scholar
  49. 49.
    Melzack R, Katz J. The McGill Pain Questionnaire: appraisal and current status. In: Turk DC, Melzack R, editors. Handbook of pain assessment. New York: Guilford Press, 1992: 152–68Google Scholar
  50. 50.
    Briggs M, Closs JS. A descriptive study of the use of visual analogue scales and verbal rating scales for the assessment of postoperative pain in orthopaedic patients. J Pain Symptom Manage 1999; 18: 438–46PubMedCrossRefGoogle Scholar
  51. 51.
    Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994; 23: 129–38PubMedGoogle Scholar
  52. 52.
    Gloth FM, Scheve AA, Stober BS, et al. The functional pain scale: reliability, validity and responsiveness in an elderly population. J Am Med Dir Assoc 2001; 2: 110–4PubMedCrossRefGoogle Scholar
  53. 53.
    Scherder EJ, Bouma A. Visual analogue scales for pain assessment in Alzheimer’s disease. Gerontology 2000; 46: 47–53PubMedCrossRefGoogle Scholar
  54. 54.
    Wynne CF, Ling SM, Remsburg R. Comparison of pain assessment intruments in cognitively intact and cognitively impaired nursing home residents. Geriatr Nurs 2000; 21: 20–3PubMedCrossRefGoogle Scholar
  55. 55.
    Huskisson EC. Measurement of pain. Lancet 1974; II: 1127–31CrossRefGoogle Scholar
  56. 56.
    Jensen MP, Karoly P, Braver S. The measurement of clinical pain intensity: a comparison of six methods. Pain 1986; 27: 117–26PubMedCrossRefGoogle Scholar
  57. 57.
    Herr KA, Mobily PR. Comparison of selected pain assessment tools for use with the elderly. Appl Nurs Res 1993; 6: 39–46PubMedCrossRefGoogle Scholar
  58. 58.
    Herr KA, Mobily PR, Kohout FJ, et al. Evaluation of the faces pain scale for the use with the elderly. Clin J Pain 1998; 14: 29–38PubMedCrossRefGoogle Scholar
  59. 59.
    Roland M, Morris R. A study of the natural history of back pain: development of a reliable and sensitive measure of disability in low-back pain. Spine 1983; 8: 141–4PubMedCrossRefGoogle Scholar
  60. 60.
    Chibnall JT, Tait RC. Pain assessment in cognitively impaired and unimpaired older adults: a comparison of four scales. Pain 2001; 92: 173–86PubMedCrossRefGoogle Scholar
  61. 61.
    Weiner D, Pieper C, Mc Connell E, et al. Pain measurement in elders with chronic low back pain: traditional and alternative approaches. Pain 1996; 67: 461–7PubMedCrossRefGoogle Scholar
  62. 62.
    Melzack R. The short-form McGill Pain Questionnaire. Pain 1987; 30: 191–7PubMedCrossRefGoogle Scholar
  63. 63.
    Herr KA, Mobily PR. Complexities of pain assessment in the elderly: clinical considerations. J Gerontol Nurs 1991; 17: 12–9PubMedGoogle Scholar
  64. 64.
    Cook AJ. Cognitive-behavioural pain management for elderly nursing home residents. J Gerontol 1998; 53: P51–9Google Scholar
  65. 65.
    Johnson M, Ashton CH, Thompson JW. An in-depth study of long-term users of transcutaneous electrical nerve stimulation (TENS): implications for clinical use of TENS. Pain 1991; 44: 221–9PubMedCrossRefGoogle Scholar
  66. 66.
    Kost RG, Strauss SE. Postherpetic neuralgia: pathogenesis, treatment, and prevention. N Engl J Med 1996; 335: 32–42PubMedCrossRefGoogle Scholar
  67. 67.
    Weiner DK, Rudy TE, Glick RM, et al. Efficacy of percutaneous electrical nerve stimulation for the treatment of chronic low back in older adults. J Am Geriatr Soc 2003; 51: 599–608PubMedCrossRefGoogle Scholar
  68. 68.
    American Geriatrics Society Panel on Exercise and Osteoarthritis. Exercise prescription for older adults with osteoarthritis pain: consensus practice recommendations. J Am Geriatr Soc 2001; 49: 808–23CrossRefGoogle Scholar
  69. 69.
    Ettinger WH, Burns R, Messier SP, et al. A randomized trial comparing aerobic exercise and resistance exercise with a health education program in older adults with knee osteoarthritis. The Fitness Arthritis and Seniors Trial (FAST). JAMA 1997; 277: 25–31PubMedCrossRefGoogle Scholar
  70. 70.
    Kanis JA. Osteoporis. Oxford: Blackwell Science Ltd, 1994Google Scholar
  71. 71.
    Ferrell BA, Josepheson KR, Pollan AM, et al. A randomized trial of walking versus physical methods for chronic pain management. Aging Clin Exp Res 1997; 9: 99–105Google Scholar
  72. 72.
    Ferrell BR. Patient education and non-drug intervention. In: Ferrell BR, Ferrell BA, editors. Pain in the elderly. Seattle: IASP Press, 1996: 35–44Google Scholar
  73. 73.
    Keefe FJ, Caldwell DS, Queen KT, et al. Pain coping strategies in osteoarthritis patients. J Consult Clin Psychol 1987; 55: 208–12PubMedCrossRefGoogle Scholar
  74. 74.
    Keefe FJ, Williams DA. A comparison of coping strategies in chronic pain patients in different age groups. J Gerontol 1990; 45: P161–5PubMedCrossRefGoogle Scholar
  75. 75.
    Wright D, Barrow S, Fisher AD, et al. Influence of physical, psychological and behavioral factors on consultations for back pain. Br J Rheumatol 1995; 34: 156–61PubMedCrossRefGoogle Scholar
  76. 76.
    Ferrell BR, Rhiner M, Ferrell BA. Development and implementation of a pain education program. Cancer 1993; 72: 3426–32PubMedCrossRefGoogle Scholar
  77. 77.
    Hirano PC, Laurent DD, Lorig K. Arthritis patient education studies, 1987–1991: a review of the literature. Patient Educ Couns 1994; 24: 9–54PubMedCrossRefGoogle Scholar
  78. 78.
    Weinberger M, Tierney WM, Booher P, et al. Can the provision of information to patients with osteoarthitis improve functional status?: a randomized controlled trial. Arthritis Rheum 1989; 32: 1577–83PubMedCrossRefGoogle Scholar
  79. 79.
    Taal E, Rasker JJ, Wiegman O. Group education for rheumatoid arthritis patients. Semin Arthritis Rheum 1997; 26: 805–16PubMedCrossRefGoogle Scholar
  80. 80.
    Mazzuca SA, Brandt KD, Katz BP, et al. Effects of self-care education on health status of inner-city patients with osteoarthritis. Arthritis Rheum 1997; 40: 1466–74PubMedCrossRefGoogle Scholar
  81. 81.
    LeFort SM, Gray-Donald K, Rowat KM, et al. Randomized controlled trial of community-based psychoeducation program for the self-management of chronic pain. Pain 1998; 74: 297–306PubMedCrossRefGoogle Scholar
  82. 82.
    Rakel B, Barr JO. Physical modalities in chronic pain management. Nurs Clin North Am 2003; 38: 477–94PubMedCrossRefGoogle Scholar
  83. 83.
    Abbot NC, Harkness EF, Stevinson C, et al. Spiritual healing as a therapy for chronic pain: a randomized, clinical trial. Pain 2001; 91: 79–89PubMedCrossRefGoogle Scholar
  84. 84.
    Braverman DL, Ericken JJ, Shah RV, et al. Interventions in chronic pain management: complementary techniques. Arch Phys Med Rehabil 2003; 84: S45–9PubMedCrossRefGoogle Scholar
  85. 85.
    World Health Organisation. Cancer pain relief with a guide to opioid availability. 2nd ed. Geneva: WHO, 1996Google Scholar
  86. 86.
    Portenoy RK. Opiod therapy for chronic non-malignant pain: current status. In: Fields HI, Libeskind JC, editors. Progress in pain research and management. Seattle: IASP Press, 1994: 247–88Google Scholar
  87. 87.
    Porter J, Jick H. Addiction rare in patients treated with narcotics [letter]. N Engl J Med 1980; 302: 123PubMedGoogle Scholar
  88. 88.
    Forman WB. Opioid analgesic drugs in the elderly. Clin Geriatr Med 1996; 12: 489–500PubMedGoogle Scholar
  89. 89.
    Fine PG. Opioid analgesic drugs in older people. Clin Geriatr Med 2001; 17: 479–87PubMedCrossRefGoogle Scholar
  90. 90.
    Max MB, Payne R, Edwards WT, et al. Principles of analgesic drug use in the treatment of acute pain and cancer pain. 4th ed. Glenville II: American Pain Society, 1999Google Scholar
  91. 91.
    Nikolaus T. Chronic pain must not simply be accepted: which analgesic for which patient? [in German]. MMW Fortschr Med 2000; 142: 968–72Google Scholar
  92. 92.
    World Health Organisation. Cancer pain relief and palliative care: report of a WHO expert committee. Geneva, Switzerland: WHO, 1990Google Scholar
  93. 93.
    Gordon DB. Pain management in the elderly. J Perianaesth Nurs 1999; 14(6): 367–72CrossRefGoogle Scholar
  94. 94.
    Phillips AC, Polisson RP, Simon LS. NSAIDs and the elderly: toxicity and economic implications. Drugs Aging 1997; 10(2): 119–30PubMedCrossRefGoogle Scholar
  95. 95.
    Murray MD, Brater DC. Nonsteroidal anti-inflammatory drugs. Clin Geriatr Med 1990; 6: 365–441PubMedGoogle Scholar
  96. 96.
    Bell GM, Schnitzer TJ. COX-2 Inhibitors and other nosteroidal anti-inflammatory drugs in the treatment of pain in the elderly. Clin Geriatr Med 2001; 17(3): 489–502PubMedCrossRefGoogle Scholar
  97. 97.
    Fu JY, Masferrer JL, Seibert K. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990; 265: 16737–40PubMedGoogle Scholar
  98. 98.
    Crofford L, Lipsky P, Brooks P, et al. Basic biology and clinical application of specific cyclooxigenase-2 inhibitors. Arthritis Rheum 2000; 43(1): 4–13PubMedCrossRefGoogle Scholar
  99. 99.
    Whelton A, Fort JG, Puma JA, et al. Cyclooxigenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001; 8(2): 85–95PubMedCrossRefGoogle Scholar
  100. 100.
    Brune K, Hinz B, Zeilhofer HU. Rational basis for the use of non-steroidal antiinflammatory drugs (and selective COX-2 inhibitors) [in German, abstract in English]. Akt Rheumatol 1999; 24: 102–8CrossRefGoogle Scholar
  101. 101.
    Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520–8PubMedCrossRefGoogle Scholar
  102. 102.
    Thomas J, Straus WL, Bloom BS. Over-the-counter non-steroidal anti-inflammatory drugs and risk of gastrointestinal symptoms. Am J Gastroenterol 2002; 97(9): 2159–61CrossRefGoogle Scholar
  103. 103.
    Monti DA, Kunkel EJS. Management of chronic pain among elderly patients. Psychiatr Serv 1998; 49(12): 1537–9PubMedGoogle Scholar
  104. 104.
    Recognition of chronic pain in elderly patients [editorial]. Trauma 2001; 43(3): 1–3, 6Google Scholar
  105. 105.
    Rainsford KD, Schweitzer A, Brune K. Autoradiographic and biochemical observations on the distribution of non-steroid anti-inflammatory drugs. Arch Int Pharmacodyn Ther 1981; 250: 180–94PubMedGoogle Scholar
  106. 106.
    Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 115: 787–96PubMedGoogle Scholar
  107. 107.
    Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual nonsteroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996 Jun; 312: 1563–6PubMedCrossRefGoogle Scholar
  108. 108.
    Shimp LA. Safety issues in the pharmacologic management of chronic pain in the elderly. Pharmacotherapy 1998; 18(6): 1313–22PubMedGoogle Scholar
  109. 109.
    AGS Panel on Chronic Pain in Older Persons. The management of chronic pain in older persons. Geriatrics 1998 Oct; 53Suppl. 3: S8–S24Google Scholar
  110. 110.
    Brune K, Beyer A, Schäfer M. Schmerz [in german]. Berlin: Springer-Verlag, 2001CrossRefGoogle Scholar
  111. 111.
    Lapane KL, Spooner JJ, Mucha L, et al. Effect of nonsteroidal anti-inflammatory drug use on the rate of gastrointestinal hospitalizations among people living in long-term care. J Am Geriatr Soc 2001; 49: 577–84PubMedCrossRefGoogle Scholar
  112. 112.
    Langman MJS, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075–8PubMedCrossRefGoogle Scholar
  113. 113.
    Andrade SE, Martinez C, Walker AM. Comparative safety evaluation of non-narcotic analgesics. J Clin Epidemiol 1998 Dec; 51(12): 1357–65PubMedCrossRefGoogle Scholar
  114. 114.
    Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory drugs. Ann Intern Med 1995; 123: 241–9PubMedGoogle Scholar
  115. 115.
    Workman BS. Management of chronic pain in older people. Aust J Hosp Pharm 1998; 28(5): 361–7Google Scholar
  116. 116.
    Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998; 338: 727–34PubMedCrossRefGoogle Scholar
  117. 117.
    Chan FKL, Hung LCT, Suen BY, et al. Celecoxib versus diclofenac and omeprozole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002 Dec; 347: 2104–10PubMedCrossRefGoogle Scholar
  118. 118.
    Meyer UA. Metabolic interaction of the proton pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol 1996; 8Suppl. 1: S21–5PubMedCrossRefGoogle Scholar
  119. 119.
    Chawla PS, Kochar MS. Effect of pain and nonsteroidal analgesics on blood pressure. WMJ 1999 Sep–Oct; 98(6): 22–25PubMedGoogle Scholar
  120. 120.
    Johnson AG, Nguyen TV, Day RO. Do nonsteroidal antiinflammatory drugs affect blood pressure? A metaanalysis. Ann Intern Med 1994; 121: 289–300PubMedGoogle Scholar
  121. 121.
    Hansson L, Zanchetti A, Carruthers SG, et al. Effects of ontensive blood-pressure lowering and low-dose aspirin in patients with hypertension: pricipal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998 Jun 13; 351(9118): 1755–62PubMedCrossRefGoogle Scholar
  122. 122.
    UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–13CrossRefGoogle Scholar
  123. 123.
    Griffin MR, Yared A, Ray WA. Nonsteroidal anti-inflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000 Mar; 151: 488–96PubMedCrossRefGoogle Scholar
  124. 124.
    Epstein M. Non-steroidal anti-inflammatory drugs and the continuum of renal dysfunction. J Hypertens 2002 Sep; 20Suppl. 6: S17–23Google Scholar
  125. 125.
    Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med 1994; 331: 1675–9PubMedCrossRefGoogle Scholar
  126. 126.
    Fored MC, Ejerblad E, Lindblad P, et al. Acetaminophen, aspirin and chronic renal failure. N Engl J Med 2001; 345: 1801–8PubMedCrossRefGoogle Scholar
  127. 127.
    Brater DC. Anti-inflammatory agents and renal function. Semin Arthritis Rheum 2002 Dec; 32 (3 Suppl. 1): 33–42PubMedCrossRefGoogle Scholar
  128. 128.
    Furst DE. Are there differences among nonsteroidal antiinflammatory drugs? Comparing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal antiinflammatory drugs. Arthritis Rheum 1994; 37: 1–9PubMedCrossRefGoogle Scholar
  129. 129.
    Rowbotham MC. Topical analgesic agents. In: Fields HL, Liebeskind JC, editors. Pharmacological approaches to the treatment of chronic pain: new concepts and critical issues. Seattle (WA): IASP Press, 1994: 211–27Google Scholar
  130. 130.
    Grahame R. Transdermal non-steroidal anti-inflammatory agents. Br J Clin Pract 1995 Jan–Feb; 49(1): 33–5PubMedGoogle Scholar
  131. 131.
    Vaile JH, Davis P. Topical NSAIDs for musculoskeletal conditions: a review of the literature. Drugs 1998; 56: 783–99PubMedCrossRefGoogle Scholar
  132. 132.
    Grace D, Rogers J, Skeith K, et al. Topical diclofenac versus placebo: a double blind, randomized clinical trial in patients with osteoarthritis of the knee. J Rheumatol 1999; 26(12): 2659–63PubMedGoogle Scholar
  133. 133.
    Airaksinen L, Venalainen J, Pietilainen T, et al. Ketoprofen 2.5% gel versus placebo gel in the treatment of acute soft tissue injuries. J Clin Pharm Ther Toxicol 1993; 31: 561–3Google Scholar
  134. 134.
    Hawkey CJ. COX-2 Inhibitors. Lancet 1999; 353: 307–14PubMedCrossRefGoogle Scholar
  135. 135.
    Chou CT, Tsai YY. A double-blind, randomized, controlled parallel group study evaluating the efficacy and safety of acemetacin for the management of osteoarthritis. Int J Clin Pharmacol Res 2002; 22(1): 1–6PubMedGoogle Scholar
  136. 136.
    Willburger RE, Wittenberg RH, Schmidt K, et al. Antiinflammatory effect of tepoxalin. Acta Orthop Scand 1998; 69(3): 295–300PubMedCrossRefGoogle Scholar
  137. 137.
    Van Hecken A, Schwartz JI, Depré M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000; 40: 1109–20PubMedGoogle Scholar
  138. 138.
    Celebrex® [prescribing information]. Karlsruhe [in German]: Pfizer, 2002Google Scholar
  139. 139.
    Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA 2000 Sep; 284(10): 1247–55PubMedCrossRefGoogle Scholar
  140. 140.
    Epstein M. Cardiovascular and renal effects of COX-2 specific inhibitors: recent insights and evolving clinical implications. Am J Ther 2001 Mar–Apr; 8(2): 81–3PubMedCrossRefGoogle Scholar
  141. 141.
    Arzneimittelkommission der deutschen Ärzteschaft: Zur Sicherheit von COX-2-Inhibitoren Deutsches Ärzteblatt 99, Ausgabe 22 vom 31.05.2002, Scite A-1535/B-1308/C-1223Google Scholar
  142. 142.
    Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and reheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002 Sep; 325: 619–23PubMedCrossRefGoogle Scholar
  143. 143.
    Depré M, Ehrich E, Van Hecken A, et al. Pharmacokinetics, COX-2 specifity, and tolerabilityof supratherapeutic doses of rofecoxib in humans. Eur J Clin Pharmacol 2000; 56: 167–74PubMedCrossRefGoogle Scholar
  144. 144.
    Truitt KE, Sperling RS, Ettinger WH, et al. A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. Aging Clin Exp Res 2001; 13: 112–21Google Scholar
  145. 145.
    Cannon GW, Caldwell JR, Holt P, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2with clinical efficacy comparable with that of diclofenac sodium. Arthritis Rheum 2000 May; 43(5): 978–87PubMedCrossRefGoogle Scholar
  146. 146.
    Mamdani M, Rochon PA, Juurlink DN, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 2002 Sep; 325: 624–7PubMedCrossRefGoogle Scholar
  147. 147.
    FitzGerald GA, Cheng Y, Austin S. COX-2 inhibitors and the cardiovascular system. Clin Exp Rheumatol 2001; 19Suppl. 25: S31–6PubMedGoogle Scholar
  148. 148.
    Ray WA, Stein CM, Daugherty JR, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002 Oct; 360: 1071–3PubMedCrossRefGoogle Scholar
  149. 149.
    White WB, Kent J, Taylor A, et al. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002; 39: 929–34PubMedCrossRefGoogle Scholar
  150. 150.
    Brater CD, Harris C, Redfern JS. Renal effects of COX-2-selective inhibitors. Am J Nephrol 2001; 21: 1–15PubMedCrossRefGoogle Scholar
  151. 151.
    Zhao SZ, Reynolds MW, Lefkowith JB, et al. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib based on the World Health Organisation/Uppsala Monitoring Centre safety database. Clin Ther 2001; 23: 1478–91PubMedCrossRefGoogle Scholar
  152. 152.
    Catella-Lawson F, McAdam B, Morrison BW. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289: 735–41PubMedGoogle Scholar
  153. 153.
    Swan SK, Rudy DW, Lasseter KC, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. Ann Intern Med 2000; 133: 1–9PubMedGoogle Scholar
  154. 154.
    Cheer SM, Goa KL. Parecoxib (parecoxib sodium). Drugs 2001; 61(8): 1133–41PubMedCrossRefGoogle Scholar
  155. 155.
    Daniels SE, Grossmann EH, Kuss ME, et al. A double-blind, randomised comparison of intramusculary and intravenuosly administered parecoxib sodium versus ketorolac and placebo in a post-oral surgery pain model. Clin Ther 2001; 23(7): 1018–31PubMedCrossRefGoogle Scholar
  156. 156.
    Grimm V, Rakoski J, Ring J. Urticaria and angioedema induced by COX-2 inhibitors. J Allergy Clin Immunol 2002; 109(2): 370–4PubMedCrossRefGoogle Scholar
  157. 157.
    Breidung R. Schmerztherapie. Stuttgart: Aesopus-Verlag, 2002Google Scholar
  158. 158.
    Bradly JD, Brandt KD, Katz BP, et al. Comparison of an antiinflammatory dose of ibuprofen and acetaminophen in the treatment of patients with osteoarthritis in the knee. N Engl J Med 1991; 325: 87–91CrossRefGoogle Scholar
  159. 159.
    Courtney P, Doherty M. Key questions concerning paracetamol and NSAIDs for osteoarthritis. Ann Rheum Dis 2002; 61(9): 767–73PubMedCrossRefGoogle Scholar
  160. 160.
    Rumore MM, Blaiklock RG. Influence of age-dependent pharmacokinetics and metabolism on acetaminophen hepatotoxicity. J Pharm Sci 1992; 81: 203–7PubMedCrossRefGoogle Scholar
  161. 161.
    Gloth FM. Pain management in older adults: prevention and treatment. J Am Geriatr Soc 2001; 49: 188–99PubMedCrossRefGoogle Scholar
  162. 162.
    Wynne HA, Cope LH, Herd B, et al. The association of age and frailty with paracetamol conjugation in man. Age Ageing 1990; 19(6): 419–24PubMedCrossRefGoogle Scholar
  163. 163.
    Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and alcohol use. JAMA 1994; 272: 1845–50PubMedCrossRefGoogle Scholar
  164. 164.
    Dart RC, Kuffner EK, Rumack BH. Treatment of pain or fever with paracetamol (acetaminophen) in the alcoholic patient: a systematic review. Am J Ther 2000; 7(2): 123–34PubMedCrossRefGoogle Scholar
  165. 165.
    Moynihan R. FDA fails to reduce accessibility of paracetamol despite 450 deaths a year. BMJ 2002; 325(7366): 678PubMedCrossRefGoogle Scholar
  166. 166.
    Van den Bemt PMLA, Geven LM, Kuitert NA. The potential interaction between oral anticoagulants and acetaminophen in everyday practice. Pharm World Sci 2002; 24(5): 201–4PubMedCrossRefGoogle Scholar
  167. 167.
    De Craen AJM, Di Giulio G, Lampe-Schoenmaeckers AJEM, et al. Analgesic efficacy and safety of paracetamol-codeine combinations versus paracetamol alone: a systematic review. BMJ 1996; 313: 325–9CrossRefGoogle Scholar
  168. 168.
    Kjaersgaard-Andersen P, Nafei A, Skov O. Codeine plus paracetamol in longer-term treatment of chronic pain due to osteoarthritis of the hip: a randomised, double-blind, multi-centre study. Pain 1990; 43(3): 309–18PubMedCrossRefGoogle Scholar
  169. 169.
    Pincus T, Swearingen C, Cummins P, et al. Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomittant use of both types of drugs in patients with osteoarthritis. J Rheumatol 2000; 27(4): 1020–7PubMedGoogle Scholar
  170. 170.
    Council for International Organizations of Medical Sciences. Benefit-risk balance for marketed drugs: evaluating safety signals. Geneva: CIOMS Working Group IV, 1998Google Scholar
  171. 171.
    Hedenmalm K, Spigset O. Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole). Eur J Clin Pharmacol 2002 Jul; 58(4): 265–74PubMedCrossRefGoogle Scholar
  172. 172.
    International Agranulocytosis and Aplastic Anemia Study. Risks of agranulocytosis and aplastic anemia: a first report of their relation to drug use with special reference to analgesics. JAMA 1986; 256: 1749–57CrossRefGoogle Scholar
  173. 173.
    Martinez Martin P, Raffaelli Jr E, Titus F, et al. Efficacy and safety of metamizol vs acetylsalicylic acid in patients with moderate episodic tension-type headache: a randomized, double-blind, placebo- and active-controlled, multicentre study. Cephalgia 2001; 21(5): 604–10CrossRefGoogle Scholar
  174. 174.
    Zylber-Katz E, Granit L, Stessmann J, et al. Effect on age on the pharmacokinetics of dipyrone. Eur J Clin Pharmacol 1989; 36: 513–6PubMedCrossRefGoogle Scholar
  175. 175.
    Novalgin® [prescribing information]. Frankfurt/Main: Avenus Pharma, 2000Google Scholar
  176. 176.
    Radbruch L, Grond S, Lehmann KA. A risk-benefit assessment of tramadol in the management of pain. Drug Saf 1996; 15(1): 8–29PubMedCrossRefGoogle Scholar
  177. 177.
    Mullican WS, Lacy JR. Tramadol/acetaminophen combination tablets and codein/acetaminophen combination capsules for the management of chronic pain: a comparative trial. Clin Ther 2001; 23: 1429–45PubMedCrossRefGoogle Scholar
  178. 178.
    Raffa RB. Pharmacology of oral combination analgesics; rational therapy for pain. J Clin Pharmacol Ther 2001; 26: 257–64CrossRefGoogle Scholar
  179. 179.
    Cicero TJ, Adams EH, Geller A, et al. A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States. Drug Alcohol Depend 1999; 57: 7–22PubMedCrossRefGoogle Scholar
  180. 180.
    Schnitzer TJ, Gray WI, Paster RZ, et al. Efficacy of tramadol in treatment of chronic low back pain. J Rheumatol 2000; 27: 772–8PubMedGoogle Scholar
  181. 181.
    Fleischmann RM, Caldwell JR, Roth SH, et al. Tramadol for the treatment of joint pain associated with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Curr Ther Res Clin Exp 2001; 62: 113–28CrossRefGoogle Scholar
  182. 182.
    Harati Y, Gooch C, Swenson M, et al. Maintenance of long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabetes Complications 2000; 14: 65–70PubMedCrossRefGoogle Scholar
  183. 183.
    Moulin D. Tramadol for the treatment of the pain in diabetic neuropathy [letter]. Neurology 1999; 52: 1301PubMedCrossRefGoogle Scholar
  184. 184.
    Tramai® [prescribing information]. Aachen: Grünenthal GmbH, 2003Google Scholar
  185. 185.
    Caldwell JR, Hale ME, Boyd RE, et al. Treatment of osteoarthritis with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double-blind, randomized, multicenter, placebo controlled trial. J Rheumatol 1999; 26: 862–9PubMedGoogle Scholar
  186. 186.
    Parris W, Johnson B, Croghan M, et al. The use of controlled-release oxycodone for the treatment of chronic cancer pain: a randomized, double-blind study. J Pain Symptom Manage 1998; 16: 205–11PubMedCrossRefGoogle Scholar
  187. 187.
    Heiskanen T, Kalso E. Controlled-release oxycodone and morphine in cancer related pain. Pain 1997; 73: 37–45PubMedCrossRefGoogle Scholar
  188. 188.
    Ytterberg S, Mahowald M, Woods S. Codeine and oxycodone use in patients with chronic rheumatic disease pain. Arthritis Rheum 1998; 41: 1603–11PubMedCrossRefGoogle Scholar
  189. 189.
    Peloso P, Bellamy N, Bensen W, et al. Double blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip or knee. J Rheumatol 2000; 27: 764–71PubMedGoogle Scholar
  190. 190.
    Brennscheidt U, Sciler KU, Thomann P. Pharmacokinetics of nortilidine and naloxone after administration of tilidine/naloxone solution or tilidine/naloxone sustained release tablets. Arzneimittel Forschung 2000; 50: 1015–22PubMedGoogle Scholar
  191. 191.
    Hajda JP, Jahnchen E, Oie S, et al. Sequential first-pass metabolism of nortilidine: the active metabolite of the synthetic opioid drug tilidine. J Clin Pharmacol 2002; 42: 1257–61PubMedCrossRefGoogle Scholar
  192. 192.
    Wehrmann T, Rausch D, Sciler KU, et al. Tilidine does not affect human sphincter of Oddi motility: a randomized, controlled study. Aliment Pharmacol Ther 1997; 11: 987–92PubMedCrossRefGoogle Scholar
  193. 193.
    Regenthal R, Kruger M, Richter M, et al. Poisoning with tilidine and naloxone: toxicokinetic and clinical observations. Hum Exp Toxicol 1998; 17: 593–7PubMedCrossRefGoogle Scholar
  194. 194.
    Wörz R, Wörz E. Long-term treatment of chronic pain with tilidine-naloxone: an analysis of 50 patients with chronic pain conditions of non-malignant origin [in German]. Fortschr Med 1995; 113: 388–92PubMedGoogle Scholar
  195. 195.
    Seiler KU, Jahnchen E, Trenk D, et al. Pharmacokinetics of tilidine in terminal renal failure. J Clin Pharmacol 2001; 41: 79–84PubMedCrossRefGoogle Scholar
  196. 196.
    Bellville JW, Forrest WH, Miller E, et al. Influence of age on pain relief from analgesics: a study of postoperative patients. JAMA 1971; 271: 1835–941CrossRefGoogle Scholar
  197. 197.
    Scott JC, Stanski DR. Decreased fentanyl and alfentanil dose requirements with age: a simultaneous pharmacokinetic and pharmacodynamic evaluation. J Pharmacol Exp Ther 1987; 240: 159–65PubMedGoogle Scholar
  198. 198.
    Kaiko RF. Age and morphine analgesia in cancer patients with postoperative pain. Clin Pharmacol Ther 1980; 28: 823–6PubMedCrossRefGoogle Scholar
  199. 199.
    Weinberg DS, Inturrisu CE, Reidenberg B, et al. Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 1988; 43: 335–42CrossRefGoogle Scholar
  200. 200.
    Tegeder I, Lotsch J, Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet 1999; 37: 17–40PubMedCrossRefGoogle Scholar
  201. 201.
    Stanski DR, Greenblatt DJ, Lowenstein E. Kinetics of intravenous and intramuscular morphine. Clin Pharmacol Ther 1978; 24: 52–9PubMedGoogle Scholar
  202. 202.
    Kaiko RF, Wallenstein SL, Rogers AG, et al. Narcotics in the elderly. Med Clin North Am 1982; 66: 1079–89PubMedGoogle Scholar
  203. 203.
    Owen JA, Sitar DS, Berger L, et al. Age-related morphine kinetics. Clin Pharmacol Ther 1983; 34: 364–8PubMedCrossRefGoogle Scholar
  204. 204.
    Baillie SP, Bateman DN, Coates PE, et al. Age and the pharmacokinetics of morphine. Age Ageing 1989; 18: 258–62PubMedCrossRefGoogle Scholar
  205. 205.
    Chan K, Kendall MJ, Mitchard J, et al. The effect of aging on plasma pethidine concentration. Br J Clin Pharmacol 1975; 2: 297–302PubMedCrossRefGoogle Scholar
  206. 206.
    Holmberg L, Odar-cederlof I, Boreus LO, et al. Comparative disposition of pethidine and norpethidine in the old and young patients. Eur J Clin Pharmacol 1982; 22: 175–9PubMedCrossRefGoogle Scholar
  207. 207.
    Herman RJ, McAllister CD, Branch RA, et al. Effects of age on meperidine disposition. Clin Pharmacol Ther 1985; 37: 19–24PubMedCrossRefGoogle Scholar
  208. 208.
    Odar-Cederlof I, Boreus LO, Bondesson U, et al. Comparison of renal excretion of meperidine and its metabolites in old and young patients. Eur J Clin Pharmacol 1985; 28: 171–5PubMedCrossRefGoogle Scholar
  209. 209.
    Hanlon JT, O’Brien JG. The pharmacological management of the elderly patient with terminal cancer pain. J Ger Drug Ther 1989; 3: 5–30Google Scholar
  210. 210.
    Allan L, Hays H, Jensen NH, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001; 322: 1154–8PubMedCrossRefGoogle Scholar
  211. 211.
    Payne R, Mathias S, Pasta D, et al. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol 1998; 16: 1588–93PubMedGoogle Scholar
  212. 212.
    Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life: The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage 1997; 13: 254–61PubMedCrossRefGoogle Scholar
  213. 213.
    Fine PG. Opioid analgesic drugs in older people. Clin Geriatr Med 2001; 17: 479–87PubMedCrossRefGoogle Scholar
  214. 214.
    Holdsworth MT, Forman WB, Killilea TA, et al. Transdermal fentanyl disposition in elderly subjects. Gerontology 1994; 40: 32–7PubMedCrossRefGoogle Scholar
  215. 215.
    Nugent M, Davis C, Brooks D, et al. Long-term observations of patients receiving transdermal fentanyl after a randomized trial. J Pain Symptom Manage 2001; 21: 385–91PubMedCrossRefGoogle Scholar
  216. 216.
    Sloan PA, Moulin DE, Hays H. A clinical evaluation of transdermal therapeutic system fentanyl for the treatment of cancer pain. J Pain Symptom Manage 1998; 16: 102–11PubMedCrossRefGoogle Scholar
  217. 217.
    Thompson JP, Bower S, Liddle AM, et al. Perioperative pharmacokinetics of transdermal fentanyl in elderly and young adult patients. Br J Anaesth 1998; 81: 152–4PubMedCrossRefGoogle Scholar
  218. 218.
    Dellemijn PL, van Duijn H, Vanneste J. Prolonged treatment with transdermal fentanyl in neuropathic pain. J Pain Symptom Manage 1998; 16: 220–9PubMedCrossRefGoogle Scholar
  219. 219.
    Lindena G, Arnau H, Liefhold J. Hydromorphone: review of pharmacological properties and therapeutic efficacy with special regard to a controlled release preparation [in German]. Schmerz 1998; 12: 195–204PubMedCrossRefGoogle Scholar
  220. 220.
    Quigley C, Wiffen P. A systematic review of hydromorphone in acute and chronic pain. J Pain Symptom Manage 2003; 25: 169–78PubMedCrossRefGoogle Scholar
  221. 221.
    Coursey CE. The psychomimetic side effects of pentazocine. Drug Intell Clin Pharm 1978; 12: 341–6Google Scholar
  222. 222.
    Li Wan Po A, Zhang WY. Systemic overview of co-proxamol to assess analgesic effects of addition of dextropropoxyphene to paracetamol. BMJ 1997; 315: 1565–71PubMedCrossRefGoogle Scholar
  223. 223.
    Gray SL, Lai KV, Larson EB. Drug-induced cognition disorders in the elderly: incidence, prevention, and management. Drug Saf 1999; 21: 101–22PubMedCrossRefGoogle Scholar
  224. 224.
    Weiner D, Hanlon JT, Studenski S. CNS drug-related fall liability in community-dwelling elderly. Gerontology 1998; 44: 217–21PubMedCrossRefGoogle Scholar
  225. 225.
    Derby S, Portenoy RK. Assessment and management of opioid-induced constipation. In: Portenoy RK, Bruera E, editors. Topics in palliative care. New York: Oxford University Press, 1997: 95–112Google Scholar
  226. 226.
    Walsh TD. Prevention of opioid side effects. J Pain Symptom Manage 1999; 5: 363–7Google Scholar
  227. 227.
    Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: II. cardiac and analgesic drugs. J Am Geriatr Soc 1999; 47: 40–50PubMedGoogle Scholar
  228. 228.
    Egbert AM. Postoperative pain management in the frail elderly. Clin Geriatr Med 1996; 12: 583–99PubMedGoogle Scholar
  229. 229.
    McQuay HJ, Carroll D, Glynn CJ. Low dose amitriptyline in the treatment of chronic pain. Anaesthesia 1992; 47: 646–52PubMedCrossRefGoogle Scholar
  230. 230.
    Leo RJ, Singh A. Pain management in the elderly: use of psychopharmacologic agents. Ann Long-Term Care 2002; 10(2): 37–45Google Scholar
  231. 231.
    Bryson HM, Wilde MI. Amitriptyline: a review of its pharmacologic properties and therapeutic use in chronic pain states. Drugs Aging 1996; 8(6): 459–76PubMedCrossRefGoogle Scholar
  232. 232.
    Lindsay PG, Olsen RB. Maprotiline in pain-depression. J Clin Psychiatry 1985 Jun; 46(6): 226–8PubMedGoogle Scholar
  233. 233.
    Ansari A. The efficacy of newer antidepressants in the treatment of chronic pain: a review of the current literature. Harv Rev Psychiatry 2000; 7: 257–77PubMedGoogle Scholar
  234. 234.
    Loldrup D, Langemark M, Hansen HJ, etal. Clomipramine and mianserin in chronic idiopathic pain syndrome. Psychopharmacology 1989; 99(1): 1–7PubMedCrossRefGoogle Scholar
  235. 235.
    Yosselson-Superstine S, Lipman AG, Sanders SH. Adjunctive antianxiety agents in the management of chronic pain. Isr J Med Sci 1985; 21: 113–7PubMedGoogle Scholar
  236. 236.
    Baron R, Wasner G, Lindner V. Optimal treatment of phantom limb pain in the elderly. Drugs Aging 1998 May; 12(5): 361–76PubMedCrossRefGoogle Scholar
  237. 237.
    Jung AC, Staiger T, Sullivan M. The efficacy of selective serotonin reuptake inhibitors for the management of chronic pain. J Gen Intern Med 1997; 12(6): 384–9PubMedCrossRefGoogle Scholar
  238. 238.
    Sindrup SH, Bjerre U, Dejgaard A, et al. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Clin Pharmacol Ther 1992 Nov; 52(5): 547–52PubMedCrossRefGoogle Scholar
  239. 239.
    Sindrup SH, Gram LF, Brosen K, et al. The selective serotonin reuptake inhibitor citalopram relieves the syptoms of diabetic neuropathy. Pain 1990 Aug; 42(2): 135–44PubMedCrossRefGoogle Scholar
  240. 240.
    Sindrup SH, Bach FW, Madsen C, et al. Venlafaxine versus imipramine in painful polyneuropathy: a randomized controlled trial. Neurology 2003 Apr 22; 60(8): 1284–9PubMedCrossRefGoogle Scholar
  241. 241.
    Chiu HF. Antidepressants in the elderly. Int J Clin Pract 1997; 51(6): 369–74PubMedGoogle Scholar
  242. 242.
    McQuay H, Carroll D, Jadad AR, et al. Anticonvulsant drugs for management of pain: a systematic review. BMJ 1995 Oct 21; 311(7012): 1047–52PubMedCrossRefGoogle Scholar
  243. 243.
    Rice ASC, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001; 94: 215–24PubMedCrossRefGoogle Scholar
  244. 244.
    Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomised controlled trial. JAMA 1998; 280: 1831–6PubMedCrossRefGoogle Scholar
  245. 245.
    Zeyfang A, Nikolaus T. Activities of daily living (ADL) are more impaired among geriatric diabetic patients compared to non diabetic subjects [abstract]. Diabetologia 2002, 45 S1 A 304Google Scholar
  246. 246.
    Khan O. Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. Neurology 1998; 51: 611–4PubMedCrossRefGoogle Scholar
  247. 247.
    Happe S, Klösch G, Saletu B, et al. Treatment of restless legs syndrome (RLS) with gabapentin. Neurology 2001; 57: 1717–9PubMedCrossRefGoogle Scholar
  248. 248.
    Bone M, Buggy D, Critchley R, et al. Gabapentin monotherapy in postamputation limb and stump pain: a randomized double-blind, placebo-controlled, cross-over study [abstract]. Eur J Anaesth 2001; 18: S2/A454CrossRefGoogle Scholar
  249. 249.
    Schachter SC, Sauter MK. Treatment of central pain with gabapentin: case reports. J Epilepsy 1996; 9: 223–6Google Scholar
  250. 250.
    Backonja M, Glanzmann RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled trials. Clin Ther 2003 Jan; 25(1): 81–104PubMedCrossRefGoogle Scholar
  251. 251.
    Laughlin TM, Tram KV, Wilcox GL. Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged and chronic nociception. J Pharmacol Exp Ther 2002 Sep; 302(3): 1168–75PubMedCrossRefGoogle Scholar
  252. 252.
    Chong MS, Libretto SE. The rationale and use of topiramate for treating neuropathiy pain. Clin J Pain 2003 Jan–Feb; 19(1): 59–68PubMedCrossRefGoogle Scholar
  253. 253.
    Szallasi A. Vanilloid receptor ligands: hopes and realities for the future. Drugs Aging 2001; 18(8): 561–73PubMedCrossRefGoogle Scholar
  254. 254.
    Watson CP, Evans PJ, Watt VR. Post-herpetic neuralgia and topical capsaicin. Pain 1988; 33: 333–40PubMedCrossRefGoogle Scholar
  255. 255.
    Peikert A, Henrich M, Ochs G. Topical 0.025% capsaicin in chronic post-herpetic neuralgia: efficacy, predictors of response and long-term course. J Neurol 1991; 238(8): 452–6PubMedCrossRefGoogle Scholar
  256. 256.
    McQuay H, Moore A. An evidence based resource for pain relief: topical capsaicin. Oxford: Oxford University Press, 1998: 249–51Google Scholar
  257. 257.
    Watson CPN. Topical Capsaicin as an adjuvant analgesic. J Pain Symptom Manag 1994; 9: 425–33CrossRefGoogle Scholar
  258. 258.
    Zhang WX, Li Wan Po A. The effectiveness of topically applied capsaicin: a metaanalysis. Eur J Clin Pharmacol 1999; 46: 517–22Google Scholar
  259. 259.
    Kastrup J, Bach FW, Petersen P, et al. Lidocaine treatment of painful diabetic neuropathy and endogenous opioid peptides in plasma. Clin J Pain 1989; 5(3): 239–44PubMedCrossRefGoogle Scholar
  260. 260.
    Dejgard A, Petersen P, Castrup J. Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet 1988; I: 9–11CrossRefGoogle Scholar
  261. 261.
    Felsby S, Nielsen J, Arendt-Nielsen L, et al. NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride. Pain 1995; 64: 283–91CrossRefGoogle Scholar
  262. 262.
    Nikolajsen L, Gottrup H, Kristensen AGD, et al. Memantine (a N-Methyl-D-Aspartate Receptor Antagonist) in the treatment of neuropathic pain after amputation or surgery: a randomized, double-blinded, cross-over study. Anesth Analg 2000; 91: 960–6PubMedCrossRefGoogle Scholar
  263. 263.
    Nikolajsen L, Hansen CL, Nielsen J, et al. The effect of ketamine on phantom pain: a central neuropathic disorder maintained by peripheral input. Pain 1996; 67(1): 69–77PubMedCrossRefGoogle Scholar
  264. 264.
    Sang CN, Booher S, Gilron I, et al. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiology 2002 May; 96(5): 1053–61PubMedCrossRefGoogle Scholar
  265. 265.
    Amin P, Sturrock ND. A pilot study of the beneficial effects of amantadine in the treatment of painful diabetic peripheral neuropathy. Diabet Med 2003 Feb; 20(2): 114–8PubMedCrossRefGoogle Scholar
  266. 266.
    Gennari C. Analgesic effect of calcitonin in osteoporosis. Bone 2002 May; 30(5 Suppl.): 67S–70SPubMedCrossRefGoogle Scholar
  267. 267.
    Silverman SL, Azria M. The analgesic role of calcitonin following osteoporotic fracture. Osteoporos Int 2002 Nov; 13(11): 858–67PubMedCrossRefGoogle Scholar
  268. 268.
    Maksymowych WP. Managing acute osteoporotic vertebral fractures with calcitonin. Can Fam Physician 1998; 44: 2160–6PubMedGoogle Scholar
  269. 269.
    Jaeger H, Maier C. Calcitonin in phantom limb pain: a double-blind study. Pain 1992; 48: 21–7PubMedCrossRefGoogle Scholar
  270. 270.
    Martinez MJ, Roque M, Alonso-Coello P, et al. Calcitonin for metastatic bone pain. Cochrane Database Syst Rev 2003; 3: CD003223PubMedGoogle Scholar
  271. 271.
    Hortobagyi GN, Theriault RL, Lester P, et al. Pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996; 335: 1785–91PubMedCrossRefGoogle Scholar
  272. 272.
    Berenson JR, Lichtenstein A, Porter A, et al. Efficacy of pamidronate in reducing skeletal events in patients with multiple myeloma. N Engl J Med 1996; 334: 488–93PubMedCrossRefGoogle Scholar
  273. 273.
    Nevitt MC, Thompson DE, Black DM, et al. Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Arch Intern Med Jan 2000; 160(10): 77–85CrossRefGoogle Scholar
  274. 274.
    Freidman DM, Moore ME. The efficacy of intraarticular steroids in osteoarthritis: a double-blind study. J Rheumatol 1980; 7: 850–6Google Scholar
  275. 275.
    Altman RD, Hochberg MC, Moskowitz RW, et al. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000; 43: 1905–15CrossRefGoogle Scholar
  276. 276.
    Hollander JL. Intrasynovial corticosteroid therapy in arthritis. Md State Med J 1970; 19: 62–6PubMedGoogle Scholar
  277. 277.
    Khojainova N, Santiago-Palma J, Kornick C, et al. Olanzapine in the management of cancer pain. J Pain Symptom Manage 2002; 23(4): 346–50PubMedCrossRefGoogle Scholar
  278. 278.
    Rumore MM, Schlichting DA. Clinical efficacy of antihistaminics as analgesics. Pain 1986; 25: 7–22PubMedCrossRefGoogle Scholar
  279. 279.
    Campbell FA, Tramèr MR, Carroll D, et al. Are cannabinoids an effective and safe treatment option for the management of pain? A qualitative systematic review. BMJ 2001; 323(7303): 13–6PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  1. 1.Bethesda Geriatric ClinicUniversity of UlmUlmGermany

Personalised recommendations